MRK Merck & Co.
FY2025 10-K
Merck & Co. (MRK) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Global pharma/animal health company; Pharmaceutical segment (89% of sales) anchored by Keytruda immunotherapy franchise generating $31.7B in FY2025
- • Keytruda Qlex (subcutaneous pembrolizumab) launched in 2025; FDA-approved September 2025 across most adult solid tumor indications — new formulation extending franchise runway beyond 2028 Keytruda compound patent expiry
Management Discussion & Analysis
- • Revenue $65.0B in 2025, up 1% YoY (+2% ex-FX) from $64.2B; US sales +13% to $36.5B, international -11% to $28.5B
- • Gross margin 74.8% vs 76.3% in 2024; GAAP EPS $7.28 vs $6.74; non-GAAP EPS $8.98 vs $7.65
Risk Factors
- • IRA price setting: Keytruda (49% of total 2025 sales) expected selected by HHS in 2027, government price effective Jan 1, 2029, U.S. sales to decline materially
- • Gardasil/Gardasil 9 China shipments paused since Feb 2025; local competitor's nine-valent HPV vaccine approved June 2025 for females 9-45 years
Financial SummaryXBRL
Revenue
$65.0B
Net Income
$18.3B
Net Margin
28.1%
ROE
34.7%
Total Assets
$136.9B
EPS (Diluted)
$7.28
Operating Cash Flow
$16.5B
Source: XBRL data from Merck & Co. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Merck & Co. Annual Reports
Get deeper insights on Merck & Co.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.